Icare, a subsidiary of Revenio Group, has today announced the launch of iCare ST500™ packing the essential features of iCare rebound tonometry technology into a modern slit lamp-based design.

iCare ST500™ slit lamp tonometer combines extreme ease of use for the eye care practitioner and unsurpassed comfort for the patient enabling faster operations and smoother acquisition, improving the efficiency of clinical workflow.

Clinical validation indicates a high correlation of IOP measurements with applanation tonometry, ensuring the clinical confidence that ST500™ can provide comparable results to the current gold standard (GAT), without disadvantages. The data also showed lower variability between repeated results for iCare ST500™ compared to GAT.

In addition to that iCare ST500™ enables accurate and repeatable operator-independent IOP measurements without the disadvantages of applanation tonometry, delivering a new standard to trust in clinical decision-making and improving workflow efficiency. With ST500™ iCare also introduces the new SmartCradle: a key element allowing users to take advantage of a powerful new rechargeable lithium battery and allowing easy connectivity and digitalization of IOP measurements in the future.

“iCare ST500™ brings the key elements of the iCare rebound technology within the slit lamp-based tonometry laid the foundations of a new era in the slit lamp-based tonometry market,” said Daniele Mantovano, iCare’s Global Business Line Director. “We’re excited to offer another great option to help eye care practitioners acquire and monitor patients' eye intraocular pressure.”

iCare ST500™ has an intuitive user interface and easy-to-follow operations. Thanks to the slit lamp mounted design it allows easy patient positioning. All the indications on the big display help in assisting the alignment and acquisition. The remote control improves the acquisition process making smoother operator’s life.

iCare ST500™ is naturally fast and has the Quick Measure feature for even faster operations in the most challenging cases. The faster the acquisition, the less stress it causes the patient, resulting in an easier life for the operator.

iCare ST500™ keeps all the unique and key advantages of rebound technology that made iCare the global leader in the tonometry ophthalmic market:

• No need for topical anesthesia nor fluorescent dye
• No need for long collateral procedures like calibration
• No need for disinfection, nor sterilization

For further information, please contact
Daniele Mantovano, Global Business Line Director
tel. +39 346 100 8040
daniele.mantovano@icare-world.com

Distribution
Main media
www.reveniogroup.fi/en

Revenio Group in brief
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand.

In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

iCare in brief
iCare is a Finnish company that develops and manufactures innovative hand-held tonometers, fundus imaging devices, perimeters and software solutions for the diagnosis and screening of eye diseases. iCare's vision is to keep the world visible to all, and its goal is to facilitate the identification and treatment of eye diseases through its technological solutions. iCare's products are reliable, efficient, and user-friendly, enabling accurate diagnoses to be made at an early stage. iCare collaborates with industry experts and is committed to continually developing new solutions to promote eye health. iCare is part of Helsinki Stock Exchange-listed Revenio Group Corporation.
www.icare-world.com